Drugs

FDA Accepts Ocular Therapeutix NDA Resubmission

FDA has accepted an Ocular Therapeutix NDA resubmission for Dextenza (dexamethasone insert) 0.4 mg for intracanalicular use for treating ocular pain occurring after ophthalmic surgery. The bioresorbable intracanalicular insert is intended for administration by a physician and is designed for drug release to the ocular surface for up to 30 days.

Last July, deficiencies cited during a preapproval inspection at an Ocular Therapeutix manufacturing facility led to an FDA complete response letter for its NDA. The letter raised concerns pertaining to unspecified deficiencies in the manufacturing process and controls section of the submission. “Satisfactory resolution of the manufacturing deficiencies identified during the FDA facility inspection is required before the NDA may be approved,” the company said at the time. Then in August, the company reported that it had addressed the inspection findings and it awaited a reinspection.

FDA has set a user fee review target date of 7/19.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome